Abstract: A method for the estimation of an immune complex and analysis of a constituent thereof, comprising a latex particle agglutination test, in which a sample comprising immune complex is incubated with coated latex particles and IgM antibodies, the latex particles coated with said complex constituent and the IgM antibodies being low affinity non-human antibodies to said complex constituent. There is also provided a kit for use in the method of the invention comprising low affinity non-human IgM antibodies to the constituent of complex undergoing analysis, and latex particles coated with said constituent.

Abstract: Method, composition of matter and kit for determining the concentration of neuroleptic drug(s) in an animal or human patient's body fluid e.g., blood serum, blood plasma, urine, saliva, spinal fluid, etc., which comprises combining the patient's body fluid with dopamine receptor material and radioactive dopamine receptor binder and then measuring the percent inhibition of binding of the radioactive binder by the drug in the patient's fluid. The kit for performing the above method includes dopamine receptor material and radioactive dopamine receptor binder.

Abstract: A chemical test kit comprising a housing, a cover for the housing. A divider in the housing divides the housing into a plurality of compartments. Each compartment has a plurality of container receiving positions, and a plurality of chemical containers are provided in the positions of each compartment. Each container has first written indicia thereon and second color indicia thereon. The containers in each compartment have different written indicia and the containers in each compartment having the same color indicia. A label in the cover contains written instructions for use of the chemicals in each compartment and is divided into portions having color indicia corresponding to the color indicia on the bottles in each compartment.

Abstract: A kit for determining the level of LDL cholesterol in body fluids is disclosed which contains a plant lectin which is a specific agglutinating agent for LDL.

Abstract: This invention relates to a novel diagnostic kit for use in radiographic bone scanning. More particularly, it relates to a kit comprising ingredients employed in the preparation of an intravenous injection of a complex of Technetium-99m, stannous ion, and an organic phosphonate identified as triethylene tetramine hexa (methylene phosphonic acid).

Abstract: A culture specimen collection and transport package for collection of a specimen and for transport thereof to a test facility. The culture specimen collection and transport package comprises an elongated stem having a swab on one end, and first and second tubular members. The first tubular member is for sterilizingly housing the swab prior to collection of a specimen, while the second tubular member contains a culture medium therein for insertion of the swab thereinto after collection of the specimen for maintaining the specimen in a viable condition during transport to the test facility. A sealing cap member is slidably mounted on the elongated stem for sealingly closing the first tubular member when the swab is disposed in the first tubular member and for sealingly closing the second tubular member when the swab is disposed in the second tubular member.

Abstract: A process for the quantitative determination of the transcobalamins TC-I, TC-II, and TC-III in serum. The process comprises incubating the serum with radiolabeled vitamin B-12, passing the resulting mixture through adsorption means, such as a charged cellulose filter or equivalent mini-column, for TC-II at a pH of about 8.5, adsorbing the remaining TC-I and TC-II components on a DEAE-cellulose type adsorbent, selectively desorbing the TC-III component with monopotassium phosphate solution of about 0.05 M and pH of about 4.6, and determining the radioactivity of each of the three transcobalamin fractions to indicate the individual and total unsaturated vitamin B-12 binding capacity of the three transcobalamins in the serum sample tested.

Abstract: A specific binding assay method and test kit for determining a ligand, particularly an antigen or hapten, in, or the ligand binding capacity of, a liquid medium, particularly a body fluid such as serum, wherein the liquid medium is combined with assay reagent means including a labeled binding component, such as a radiolabeled form of the ligand, with the improvement that separation of the resulting bound-species and free-species of the labeled component is accomplished by selectively adsorbing the free-species onto a solid comprising a nonion-exchange cross-linked styrene polymer. The method is particularly suited to the radioimmunoassaydetection of nonproteinaceous haptens such as thyroxine, triiodothyronine, estriol, vitamin B.sub.12 and digoxin. The styrene polymer adsorbent provides a very effective and readily available separation means for use in specific binding assays.

Abstract: A specific binding assay method and test kit for determining a ligand, particularly an antigen or hapten, in, or the ligand binding capacity of, a liquid medium, particularly a body fluid such as serum, wherein the liquid medium is combined with assay reagent means including a labeled binding component, such as a radiolabeled form of the ligand, with the improvement that separation of the resulting bound-species and free-species of the labeled component is accomplished by selectively adsorbing the free-species onto a solid comprising a nonion-exchange cross-linked polyvinyl alcohol. The method is particularly suited to the radioimmunoassay detection of nonproteinaceous haptens such as thyroxine, triiodothyronine, estriol, vitamin B.sub.12 and digoxin. The polyvinyl alcohol adsorbent provides a very effective and readily available separation means for use in specific binding assays.

Abstract: A ready-for-use rapid test package for carrying out serological investigations in which at least two of the following reactants:(1) patients serum;(2) erythrocytes;(3) amboceptors specific for the erythrocytes;(4) complement and(5) a reactant selected from the group consisting of antigen and antibodies not belonging to reactant class (3)Are reacted with each other, the package containing at least two of the reactants in a solid and preserved form, in quantities suitably adjusted to each other, to carry out the test.The package provides the clinician or serological laboratory with reliable and simple means of carrying out the complement binding reaction without the complicated adjustments of the activities of the different reactants.

Abstract: The onset of ovulation in a female is detected by measuring the water content of the cervical mucus. A pellet made of a water-swellable polymer is inserted into the vagina. The increase in the size of the pellet, that occurs owing to contact with the vaginal mucus for a selected period of time, is measured. The size of the pellet sharply increases at or about the onset of ovulation.

Abstract: This invention is directed to a method and means for the early detection of a wide variety of cancers, in humans, which method and means consists of the assay and development of a pattern or fingerprint of severally biologically inert, or inactive polypeptides (or perhaps biologically active peptides) in the blood of humans, e.g.: big-ACTH (big-Adrenocorticotropin Hormone), big-.beta.MSH (big-beta melanocyte-stimulating Hormone), the alpha chain of the glycopeptide hormones, the measurement of the arginine vasotocin (AVT), an analogue of Arginine vasopressin, (AVP) (or the combined measurement of AVP and AVT). The values obtained by the assays of each of the foregoing polypeptids is then compared with the individual values and patterns found in humans. If any one of the polypeptide values is elevated above the upper end of the normal values, a carcinoma from some tumor site is suspected; also from the pattern of elevations in one or more peptides, a specific type of cancer may be suspected.

Abstract: A specific test for active demyelinzation is based on a discovery that free myelin basic protein can be detected in cerebrospinal fluid by the use of a radioimmunoassay, and that the level of basic protein found corresponds to the activity of demyelinating pathologies. A simple method is utilized, wherein samples of cerebrospinal fluid are assayed and the results of the assay are compared with standard samples of myelin basic protein. Patients with active demyelinating diseases have high levels (17-100ng/ml) of basic protein; those with progressive pathologies have less (6-16 ng/ml); and those in remission have less than 4 ng/ml, comparable to the control population.

Abstract: Novel folic acid derivatives useful in processes for analysis of biological fluids for folic acid or its metabolites comprising components of the formula: ##STR1## wherein R is hydrogen or radioactive iodine.

Abstract: Process for ultramicro-quantitative determination of acetone comprising (1) reacting radioactive molecular or cationic iodine with the acetone contained in a sample from biological preparations in a strong alkaline solution to produce radioactive iodoform according to a haloform reaction quantitatively, (2) reducing the non-reacted molecular or cationic radioactive iodine to a radioactive iodide, (3) separating the radioactive iodoform from the radioactive iodide, and (4) measuring the radioactivity of the radioactive iodoform by any conventional method. Two types of assay kits suitable for use in this determination of acetone comprise respectively:(A)Reagent 1 = a radioactive iodide;Reagent 2 = an oxidizing agent;Reagent 3 = an alkali agent;Reagent 4 = a reducing agent;Reagent 5 = an acetone standard solution;Reagent 6 = a surface active agent; andReagent 7 = an anion exchanger.

Abstract: A novel human cancer associated protein, termed C1 IAC, having C1 inactivator-like function, diagnostic tests based on demonstrating the presence of C1 IAC, antibodies and antisera with specificity against C1 IAC, matrix-immobilized antibodies, and the therapy of human cancer using antisera or antibodies with specificity against C1 IAC. Also, a novel human cancer associated protein, termed CAAC, and antisera and antibodies with specificity against CAAC. The use of rabbit antihuman C1 IA and antihuman C4 for monitoring cancer diseases.

Abstract: An improved method for identification and qualitative determination of potentially harmful pollutants in water through the use of a novel sampling test tube apparatus which consists essentially of a test tube containing a foam cube which has been impregnated with a detection chemical solution selected to react colorimetrically with specific pollutants to be detected.

Abstract: A pre-packaged patient identification kit and method for assuring correlation between a patient, his specimens and his records is disclosed. The kit is preferably formed as a transparent package inside of which a wristband, at least one specimen container and, optionally, a label are disposed. The wristband, specimen container, and label are pre-numbered with identical patient identifying indicia. The kit is used by first visually verifying that all indicia are identical, attaching the wristband to the patient, taking a specimen from the patient and placing it in the specimen container, and placing the label means on the patient's record. After analysis of the specimen, the patient identifying indicia is copied onto a label for a therapeutic agent to be given to the patient; and finally, before administration of the therapeutic agent to the patient, the indicia on the label of the therapeutic agent is checked against the indicia on the patient's wristband and his records.

Abstract: An assay kit for assaying adenosine-3',5'-cyclic monophosphate, which is herein referred to as cAMP, guanosine-3',5'-cyclic monophosphate, which is herein referred to as a cGMP, or both; and said assay kit comprising,A container of Reagent 1 comprising succinyl cAMP tyrosine methyl ester; succinyl cGMP tyrosine methyl ester; succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in admixture or both succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in separate containers, said esters labelled with radioactive iodine;A container of Reagent 2 comprising an anti-cAMP serum, an anti-cGMP serum, an anti-cAMP and anti-cGMP serum in admixture or both anti-cAMP serum and anti-cGMP serum in separate containers;A container of Reagent 3 comprising an imidazole buffer solution of 0.

Abstract: A radioassay system for the determination of methotrexate in biological fluids based on the competitive binding of labeled and unlabeled methotrexate to the enzyme dihydrofolate reductase. Samples of unknown methotrexate level are mixed with I.sup.125 labeled methotrexate. A portion of the total methotrexate present is bound by the addition of enzyme, and the unbound methotrexate is removed with charcoal. The level of bound I.sup.125 labeled methotrexate is measured in a gamma counter. To calculate the methotrexate level of the unknown samples, the displacement of bound labeled methotrexate caused by the unknowns is compared to the displacement caused by known methotrexate standards.